Drug Discovery World

SEPTEMBER 17, 2024

I am the lead scientist on our oncology and infectious disease programmes, where I manage and oversee everything related to drug discovery and work closely with our VP of Clinical Operations on our clinical trials. Administration of these cancer immunotherapies is therefore restricted only to tertiary cancer centres.

Research 221

Research Clinical Trials Disease Trials 221

Drug Discovery World

AUGUST 23, 2023

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. In infants and children, the risk of RSV-associated LRTD is highest during the first year of life.

FDA Approval 130

FDA Approval Vaccine FDA Virus 130

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Drug Discovery World

AUGUST 31, 2022

The study authors suggest that antigen levels could help determine those patients most likely to benefit from therapies directed at fighting the virus. . Analysis of Covid patient blood samples. High blood antigen levels also correlated with some known risk factors for worse illness, such as being male.

Hospitals 130

Hospitals Trials Virus International 130

Drug Discovery World

SEPTEMBER 13, 2023

The first months of the trial have already confirmed that the W-ENV protein is present in the blood of over 25% of patients with persistent syndromes who suffered from Long Covid. times more than the control group.

Protein Expression 130

Protein Expression Clinical Trials Hospitals Trials 130

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus. Unsubscribe any time.

RNA 87

RNA Virus DNA Vaccine 87

The Pharma Data

APRIL 8, 2022

Using a Human Lung Chip that replicates the structures and functions of the lung air sac, or “alveolus,” the research team discovered that applying mechanical forces that mimic breathing motions suppresses influenza virus replication by activating protective innate immune responses. During his Ph.D.

Virus 52

Virus Immune Response Disease Clinical Trials 52

The Pharma Data

JUNE 7, 2023

RSV is a common, contagious respiratory virus that leads to over 270,000 hospitalisations and approximately 20,000 in-hospital deaths each year in adults aged 60 years and over in Europe. The authorisation is based on GSK’s landmark positive pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial data.

Virus 40

Virus Vaccine Disease Trials 40

The Pharma Data

NOVEMBER 5, 2020

Regeneron announced today an update from the independent data monitoring committee (DMC) for the United Kingdom-based RECOVERY trial evaluating REGN-COV2 in hospitalized patients with COVID-19. The DMC letter is available here: [link]. Department of Health and Human Services under OT number: HHSO100201700020C.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. It forms part of the UK Recovery Trial, which found that a cheap steroid called dexamethasone could save lives. We need to know, and the way to know is to do the trials that will tell us whether that hope turns into reality.”.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

AUGUST 20, 2020

Medical detection dogs Bramble (left) and Lexi during a visit to Kettering General Hospital. NHS staff are taking part in a trial to see if dogs can sniff out Covid-19 – even in people who are asymptomatic. If the trial is successful, the dogs could be used at UK airports to screen people arriving from abroad.

Trials 52

Trials Nurses Hospitals Virus 52

The Pharma Data

JANUARY 27, 2021

COVID-19 Antibody Treatments Exceed Expectations in Early Trials. 27, 2021 — Promising new data on two antibody cocktails suggest these therapies can keep COVID-19 patients out of the hospital and even prevent illness altogether in some people. All tested negative for the virus but live with someone who has COVID-19.

Treatment 52

Treatment Trials Hospitals Virus 52

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial.

Hospitals 52

Hospitals Trials International Clinical Trials 52

Drug Discovery World

JANUARY 11, 2024

Messenger RNA therapies are also currently being investigated in other rare inherited metabolic diseases – propionic and methylmalonic acidaemias – in global clinical trials sponsored by Moderna, including at Great Ormond Street Hospital for Children. mRNA contains instructions that direct the cells to make proteins.

Disease 147

Disease Research RNA Therapies 147

The Pharma Data

MAY 16, 2022

million symptomatic cases of the virus, as well as 690,000 hospitalizations and more than 110,000 deaths. The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics.

Vaccine 52

Vaccine Hospitals Virus Production 52

The Pharma Data

OCTOBER 28, 2020

Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 23, 2020

23, 2020 — Because COVID-19 is known to raise the odds for dangerous blood clots, blood thinners have quickly become part of routine care for many hospitalized patients. The three trials are being conducted on four continents. WEDNESDAY, Dec. “Such abnormal bleeding could be lethal if not quickly diagnosed and treated.”

Trials 52

Trials Hospitals Clinical Trials Doctors 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

Drug Discovery World

FEBRUARY 27, 2023

The trial patients were six to 24 months of age at the time of administration of OTL-201, and the preliminary results are based on a median follow-up of two years (range: nine to 30 months). The patient’s modified blood stem cells, now including a working copy of the SGSHgene, are then given back to the patient.

Therapies 130

Therapies Trials Virus Disease 130

The Pharma Data

SEPTEMBER 1, 2020

Sanofi is halting clinical trials treating serious COVID-19 patients with its Kevzara drug after the data proved inconclusive. The Phase 3 trial did not meet the primary or secondary endpoints compared with placebo and established hospital care. Conor Kavanagh. Source link.

Trials 52

Trials Treatment Clinical Trials Vaccine 52

Drug Discovery World

JULY 3, 2023

In the Modulating Tumour Microenvironment programme, experts took a deeper look at the results we are seeing from emerging immunotherapies such as immune checkpoint blockade and chimeric antigen receptor T cells (CAR Ts), and also discussed advances in our understanding of and strategies to modulate the tumour microenvironment.

Engineering 130

Engineering Virus Therapies Treatment 130

Drug Discovery World

FEBRUARY 5, 2024

Science and technology innovator Danaher launched a strategic collaboration with Cincinnati Children’s Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials.

Small Molecule 162

Small Molecule Assay Development Production Science 162

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The trial on 10,000 people will now see if the vaccine can prevent people getting ill.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. Acute and persistent symptoms in non-hospitalized PCR- confirmed COVID-19 patients,” Sci Rep, vol. F Ceban et al., Academic Press Inc., 93–135, Mar.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

Drug Discovery World

JULY 12, 2022

The report highlights the need to accelerate clinical trials for AMR-related vaccines in late-stage development and also to maximise the use of current existing vaccines. . The report also highlights the challenges of vaccine innovation and development, with a focus on pathogens associated with hospital-acquired infections (HAI).

Vaccine 130

Vaccine Hospitals Clinical Trials Disease 130

The Pharma Data

DECEMBER 3, 2020

Another record-breaking day of COVID-19 hospitalizations and deaths underscored Redfield’s grim warning. The number of people hospitalized for COVID-19 on Wednesday passed 100,000, nearly double the highest point seen last spring. With hospitals filling up in multiple states, the days ahead do appear bleak.

Hospitals 52

Hospitals Long-Term Care Facilities Vaccine Nurses 52

The Pharma Data

OCTOBER 30, 2020

30, 2020 /PRNewswire/ — The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial. NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

Followed by Russia , Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020. Currently, it is smoothly progressing with the approval for Phase 2 clinical trials in four countries, and it is expected to see the results sequentially starting as early as the third quarter of 2021.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

JANUARY 21, 2021

Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus’ ability to replicate quickly and spread to nearby healthy cells.

Trials 52

Trials Treatment Small Molecule Hospitals 52

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Trials Hospitals Treatment 52

The Pharma Data

MARCH 11, 2021

This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The full results of the trial will be submitted for publication in a peer-reviewed journal later this year.

Trials 52

Trials Hospitals Treatment Science 52

The Pharma Data

AUGUST 7, 2020

The governing body claims this proposal could have positive effects on mitigating burdensome requirements for gene therapy clinical trials in the future. In this light, Pharma IQ’s weekly round-up focuses on advancing therapies and clinical trials to combat Covid-19.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

Codon

JANUARY 21, 2024

Human challenge trials were an indispensable part of the development of the malaria vaccine, R21/Matrix-M, endorsed by the World Health Organization last October. But for all of their benefits, human challenge trials have their drawbacks. Jake himself has participated in both Zika and Shigella challenge trials.

Vaccine 111

Vaccine Trials Disease Virus 111

NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

The first indication that those hopes might be realized came from the announcement just a month ago of a 50 percent reduction in hospitalizations from the Merck and Ridgeback drug molnupiravir (originally developed with an NIH grant to Emory University, Atlanta). But would it work to treat COVID-19 in an infected person?

Clinical Trials 52

Clinical Trials Virus Hospitals FDA 52

The Pharma Data

OCTOBER 19, 2020

Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen. The randomized, double-blind, placebo-controlled trial is expected to enroll 900 patients across approximately 20 countries. BOSTON and DURHAM, N.C.,

Trials 40

Trials Hospitals Therapies Clinical Trials 40